Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week. Topics include all stories related to hepatitis C as well as personal stories and events.
Week Ending 10/19/2014
‘Drugs that cure patients can kill profits. So Gilead Sciences Inc. faced a fiscal challenge with its new drug, Sovaldi, which reportedly cures up to 90 percent of people with hepatitis C, a viral infection that can lurk undiagnosed and transmissible for decades until it causes liver diseases such as cirrhosis and cancer.’
‘PHILADELPHIA — Distance to a primary care provider office for a patient was shorter compared with a hepatologist, gastroenterologist or infectious disease specialist that can provide screening for hepatitis C virus infection, according to data presented at IDWeek 2014.’
‘Hepatitis C virus (HCV) core-antigen testing is a highly reliable way of diagnosing acute HCV infections in people living with HIV, investigators from the United Kingdom report in the online edition of Clinical Infectious Diseases.’
‘On Tuesday, 10/14/14, the cross-government working group supporting and monitoring the implementation of the updated Viral Hepatitis Action Plan—the Viral Hepatitis Implementation Group or “VHIG”—met in Washington, DC to share updates on 2014 accomplishments and plans for the coming year.’
‘Viral hepatitis, specifically hepatitis C virus infection, was prevalent among the population in southeastern Washington, D.C., according to data presented at IDWeek 2014. “The prevalence of hepatitis C infection at our hospital is significant and unexpected,” Joshua Stierwalt, candidate, George Washington University Master of Public Health-Epidemiology, told Healio.com/Hepatology.’